Learn More >

Ministry Status: Recovery


The ministry is resuming regular operations and supporting health sector stabilization.

Biosimilars: Information for Patients

Overview

On December 20, 2022, Ontario expanded the use of biosimilar drug treatments for Ontarians. Starting on March 31, 2023, Ontario Drug Benefit (ODB) recipients who are on an originator biologic will begin to transition to a Health Canada approved biosimilar version of the drug.

A transition period will occur between March 31, 2023 and December 29, 2023 to allow ODB program recipients to switch from an originator biologic to a biosimilar version in order to maintain ODB program coverage for their biologic. ODB program recipients will be required to switch to a biosimilar version before December 29, 2023, in order to maintain ODB program coverage for their biologic, unless an exception applies.

Biosimilar drugs are proven to be as safe and effective as the alternative higher priced originator biologic drugs and are able to treat many of the same conditions. Numerous studies show little to no difference in safety and efficacy when patients move to a biosimilar.

Patients will continue receiving the same high-quality treatment, while allowing the government to fund more new drug therapies, bring innovation to the health care system and continue its work to deliver better, connected patient care.  

Will I be affected?

If you’re taking Copaxone®1, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, or Rituxan® you may need to switch to the biosimilar drug to get coverage through the ODB program. If you have a medical reason why you can’t switch to the biosimilar, your specialist, doctor or nurse practitioner may request an exemption for you that will be considered on a case-by-case basis through the Exceptional Access Program. 

Your specialist, doctor or nurse practitioner will need to provide you with a new prescription for the biosimilar version of the drug that you will be using.

For ODB program recipients taking Remicade® or Rituxan®, as part of the biosimilar transition, you may have to go to a new infusion centre to receive your infliximab or rituximab infusion.

For ODB program recipients who are self-administering their biologic product at home but who are affiliated with a patient support program, you may need to be enrolled in a new patient support program associated with the biosimilar you will be using.

As new biosimilars are approved by Health Canada, and enter the Canadian market, additional biologic drugs may be included as part of this policy change.

Ask your specialist, doctor, nurse practitioner or pharmacist for more information about how the change will affect you.

Affected Drugs

ODB Program Coverage

Drug

Originator Biologic

(Recipients must transition to the biosimilar version before

December 29, 2023)

Biosimilars Funded Under ODB Program Effective March 31, 2023

Indications

(Transition for other indications funded on a case-by-case basis which may not appear on the below list also applies)

Adalimumab

Humira®

Abrilada®

Amgevita®

Hadlima®

Hulio®

Hyrimoz®

Idacio®

Simlandi®

Yuflyma®

 

Ankylosing Spondylitis

Crohn’s Disease

Hidradenitis Suppurativa

Plaque psoriasis

Polyarticular Juvenile Idiopathic Arthritis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Uveitis

Etanercept

Enbrel®

Brenzys®

Erelzi®

Ankylosing spondylitis

Plaque psoriasis

Polyarticular juvenile Idiopathic arthritis

Psoriatic arthritis

Rheumatoid arthritis

Glatiramer acetate

Copaxone®

Glatect®

Relapsing Remitting Multiple Sclerosis (RRMS)

Infliximab

Remicade®

 

Avsola®

Inflectra®

Renflexis®

 

Ankylosing spondylitis

Crohn’s Disease

Plaque psoriasis

Psoriatic arthritis

Rheumatoid arthritis

Ulcerative Colitis

Insulin aspart

NovoRapid®

Kirsty®

Trurapi®

Diabetes (Type 1 and 2)

Insulin glargine

Lantus®

Basaglar®

Semglee®

Diabetes (Type 1 and 2)

Insulin lispro

Humalog®2

Admelog®

Diabetes (Type 1 and 2)

Rituximab

Rituxan®

Riabni®

Riximyo®

Ruxience®

 Truxima™

Rheumatoid Arthritis

Granulomatosis with Polyangiitis (GPA or Wegener’s Granulomatosis) Microscopic Polyangiitis (MPA)

Originator Biologics vs. Biosimilars

Biologics are medicines made from substances found in living things. They are often used to treat diseases such as cancer, immune system disorders and diabetes.

A biosimilar biologic drug is a highly similar but generally less expensive version of an originator biologic drug. When a company develops a new biologic drug, that company has the sole right to make and sell the drug for awhile. After that period ends, other companies can start making their own version. The biologic drug that other companies make is the biosimilar drug.

Biosimilars are not exactly the same as originator biologics. Health Canada does a lot of testing and has clearly said that biosimilars are just as safe and effective as the originator biologic drugs.

Process for Switching

If you are using a biologic that is included in the policy:

  • Make an appointment as soon as possible during the transition period, with your specialist, doctor or nurse practitioner.  Your specialist, doctor or nurse practitioner is also receiving information on the policy change and may be reaching out to you.
  • Discuss transitioning to the biosimilar with your specialist, doctor, nurse practitioner or pharmacist. Note that only your specialist, doctor or nurse practitioner will be able to write a new prescription for you.
  • Your specialist, doctor or nurse practitioner will explain the transition process, discuss your options, write you a new prescription, and help enroll you in a patient support program, if applicable.

Preventing the Nocebo Effect

The nocebo effect occurs when a patient’s negative expectations affect the treatment outcomes. A patient’s mindset can impact their perceived symptoms and their sense of well-being.

To combat against a potential nocebo effect, you can:

  • Acknowledge the nocebo effect
  • Inform yourself about biosimilars
  • Discuss biosimilars with your specialist, doctor, nurse practitioner or pharmacist and what it means for you
  • Keep a neutral or positive outlook
  • Stay informed about the switch process

Resources

For more information and/or reading materials, see the resources below.

FAQs for Patients

Why is coverage for biologic drugs changing?

Every year, ODB program covers new treatments to ensure that Ontarians have access to new and innovative drug therapies. Currently, ODB program recipients have access to coverage for over 5,000 safe and effective medications.

Biologic medicines have improved the treatment of many disabling and life-threatening diseases.

Patients will continue receiving the same high-quality treatment, while allowing the government to fund more new drug therapies, bring innovation to the health care system and continue its work to deliver better, connected patient care.

Biosimilars have been used in the European Union for more than 15 years and Ontario is following a number of Canadian jurisdictions, including British Columbia, Alberta, New Brunswick, Quebec, Northwest Territories, Nova Scotia and Saskatchewan, to expand the use of biosimilar medications.

What is the difference between an originator biologic and a biosimilar?

Lantus®, Enbrel®, Remicade®, Rituxan®, Humalog®, Humira® and NovoRapid® are originator biologic drugs. An originator biologic is the first version of a biologic drug. Once an originator biologic’s market exclusivity ends, other manufacturers can start producing highly similar versions of originator biologics, called “biosimilar” drugs that work in the same way. These biosimilars do not have the same costs to bring the product to market and can be offered at a much lower cost.

Biosimilars are not identical to originator biologics. However, Health Canada conducts rigorous testing to ensure that biosimilars have a highly similar structure, are equally as safe, and have the same therapeutic effect as the originator biologic. The Ontario government is confident in the safety and efficacy of biosimilars based on our experience over the past 10 years, as well as the experiences of many countries around the world.

Health Canada is responsible for ensuring the safety, efficacy, and quality of all drugs. For a biosimilar drug to be approved in Canada, Health Canada must find no meaningful differences in safety and effectiveness compared to the originator biologic. The biosimilars included in Ontario’s expanded biosimilars policy have all been approved by Health Canada and are already in widespread use.

Are Copaxone® and Glatect® biologics?

Copaxone® and Glatect® are both glatiramer acetate products manufactured and marketed by different companies.

Glatiramer acetate is classified as a non-biologic complex drug (NBCD). Such as the case for biosimilars, Glatect® is a highly similar and more affordable version of the brand medication Copaxone®. Health Canada has conducted rigorous testing to ensure Glatect® is safe and effective.

What are the benefits of biosimilars?

Health Canada supports the safety and efficacy of biosimilar drugs. You should not expect any changes to your health outcomes resulting from your transition from an originator biologic to a biosimilar.

Patients will continue receiving the same high-quality treatment, while allowing the government to fund more new drug therapies, bring innovation to the health care system and continue its work to deliver better, connected patient care.

Are biosimilars safe? Will they work for me?

Biosimilar biologics must fulfill rigorous regulations and testing requirements imposed by Health Canada to prove they are just as safe and effective as the originator biologic. Health Canada has definitively commented on the safety of biosimilars, stating that its rigorous standards for authorization mean that patients and health care providers can have the same confidence in the quality, safety and efficacy of a biosimilar as the originator biologic.

There are rare circumstances where medical exemptions make it appropriate for an ODB program recipient to continue to receive coverage for an originator biologic.  These exemptions will be considered on a case-by-case basis.

Once the transition period has begun, speak with your specialist, doctor or nurse practitioner to discuss your options. Your specialist, doctor or nurse practitioner will determine whether to request an exemption for you.

What biologic products are being transitioned?

This change will impact you if you are taking any of the following originator biologic drugs: Enbrel® (etanercept), Humalog® (insulin lispro), Humira® (adalimumab), Lantus® (insulin glargine), NovoRapid® (insulin aspart), Remicade® (infliximab), or Rituxan® (rituximab). This change will also impact you if you are taking Copaxone® (glatiramer), which is a non-biologic complex drug (NBCD).

If you are taking any of the medications mentioned above, you may require a new prescription to continue to receive ODB program coverage for your medication(s). This new prescription would allow you to transition from the originator biologic drug that you are currently on to a biosimilar version. We encourage you to speak to your healthcare professional to discuss this transition.

What do I have to do to transition to the biosimilar drug?

  1. Make an appointment as soon as possible during the transition period, with your specialist, doctor or nurse practitioner. Your specialist, doctor or nurse practitioner is also receiving information on the policy change and may be reaching out to you.
  2. Discuss transitioning to the biosimilar with your specialist, doctor, nurse practitioner or pharmacist. Note that only your specialist, doctor or nurse practitioner will be able to write a new prescription for you.
  3. Your specialist, doctor or nurse practitioner will explain the transition process, discuss your options, write you a new prescription, and help enroll you in a patient support program, if applicable.

If I transition to a biosimilar, do I have to go to a different infusion centre?

If you take Remicade® or Rituxan®, as part of the biosimilar transition you may have to go to a new infusion centre to receive your infliximab or rituximab infusion.

The Ministry of Health has been working closely with our health care partners to ensure that ODB Program recipients who require an infusion have access to an infusion clinic that can deliver the biosimilar. Infusion clinics in Ontario are ready to support ODB program recipients with their transition to a biosimilar.

We encourage you to speak to your healthcare professional for more information.

What clinical evidence supports the safety and efficacy of transitioning from an originator biologic to a corresponding biosimilar?

Biosimilar biologics must fulfill rigorous regulations and testing requirements imposed by Health Canada to prove they are as safe and effective as the originator biologic. Health Canada has definitively commented on the safety of biosimilars, stating that its rigorous standards for authorization mean that patients and health care providers can have the same confidence in the quality, safety and efficacy of a biosimilar as the originator biologic.

Clinical trials and registry data findings are regularly reported at annual scientific meetings around the world that indicate that transitioning from an originator biologic to a biosimilar is safe and effective. There are now more than 100 research studies in rheumatology, gastroenterology, dermatology and other diseases, which collectively show little to no clinical differences between biosimilars and originator biologics.

The Ministry of Health will be carefully monitoring drug usage and feedback from ODB program recipients and healthcare practitioners both during and after the implementation of this funding policy regarding biosimilars.

See Question three above for information about the clinical evidence to support switching from the originator non-biologic complex drug Copaxone® to the similar version, Glatect®.

What are patient support programs?

Some biosimilar manufacturers provide patient support programs (PSP) and services, along with access to infusion centres, similar to those of the originator biologic drug. If applicable, specialists, doctors or nurse practitioners can help initiate the enrolment process into a PSP.

What if I have private coverage?

Please talk to your insurer. The Ministry of Health does not maintain information on private insurance policies for biologics or any other prescription medications.

Patient Support Programs

Abrilada®

Registering to the PfizerFlex Patient Support Program gives:

  • Live support for questions about the program or treatment;
  • Reimbursement expertise;
  • Experienced team members to help you access your medication as quickly as possible;
  • Access to a reliable infusion/injection clinic network, staffed by qualified healthcare professionals;
  • Practical tools to help you navigate your treatment plan.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: 1-855-935-FLEX (3539)

Fax number: 1-833-958-3539

Website: www.abrilada.ca

Amgevita® and Avsola®

Amgen Biosimilar patients, living in Ontario, will receive the same level of support and services that Enbrel® patients have received through the Enliven program by Amgen Entrust Patient Support Services over the last 20+ years.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: 1-877-936-2735

Fax number: 1-833-423-0252

E-mail: amgevita@oneenliven.ca (for Amgevita®) OR avsola@oneenliven.ca (for Avsola®) OR info@oneenliven.ca (for general inquiries)

Website: www.amgevita.ca; www.avsola.ca;

Brenzys®, Renflexis® and Hadlima®

HARMONY BY ORGANON Patient Support Program

The HARMONY BY ORGANON™ Patient Support Program provides eligible patients access to:

  • A designated HARMONY BY ORGANON™ Coordinator
  • Comprehensive reimbursement support and assistance with special authorization (SA) forms
  • Financial assistance, temporary bridging, and coverage of additional doses when applicable
  • Monitoring and lab testing support
  • Vaccination support
  • Paid subscription to the LyfeMD app, a lifestyle intervention-based program that focuses on nutrition, yoga, breathing, mindfulness, and physical activity programs.

Additional services for HADLIMA® and BRENZYS®:

  • Coordination with patient’s preferred pharmacy
  • Self-injection training options to help patients get started on treatment
  • On-going injection support
  • Extended travel assistance program including a travel case and travel documentation

Additional services for RENFLEXIS®:

  • Infusion appointment coordination
  • Network of approximately 600 clinics across Canada

HARMONY BY ORGANON™ has a Patient Support Team and services to help create a personalized journey for those enrolled. We are an experienced partner that can help you support your patients through customized enrollment options and transition plans.

To enroll a patient in the HARMONY BY ORGANON™ Patient Support Program, please contact the Program: 

Toll free number: 1-866-556-5663 (Monday to Friday 8:00 am to 8:00 pm EST)

Fax number: 1-866-240-4076

E-mail: info@harmonybyorganon.ca

Erelzi®

The XPOSE® Patient Support Program provides services that are designed to help patients get quickly started with ERELZI® and support them throughout their treatment.

  • A dedicated support team that is available to assist patients and Health Care Providers with reimbursement, paperwork, prescription renewal reminders, record keeping of patient documents, and injection training services.
  • A seamless enrollment process flexible to Health Care Provider’s preference
  • Provincially expert reimbursement navigation and adapted financial assistance
  • Injection services with tailored options for patient convenience
  • Continually updated clinical support services for patients
  • Services and support adapted to each patient category and age group
  • Health management support and education for physicians, nurses and pharmacists
  • Specific services to assist community pharmacists supporting patients on biosimilars

To enroll a patient or have any of your questions answered, please contact the XPOSE® Patient Support Program either through our toll free number or e-mail address and speak with your Case Worker and/or Field Case Manager.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: (888) 449-7673

Fax number: (844) 449-7673

E-mail: xpose@sandozprogramsupport.ca

Glatect®

The Ally Patient Support Program has been designed to provide Canadian Multiple Sclerosis RRMS patients and their healthcare professionals, efficient, value-added service aimed at insuring rapid treatment onset and sustained medication compliance on GLATECT. The Ally Patient Support Program consists of:

  • Patient Enrolment
  • Initial Welcome Call
  • Provision of no cost goods support program
  • Compliance and Adherence Monitoring through patient follow up calls by ALLY Program Representatives to ensure Patient program satisfaction and medication compliance
  • Patient Self-Injection Training upon the first injection by a Nurse or web-based questions (Telephonic or by Field RN’s) and subsequent trainings as needed available upon request
  • Reimbursement Navigation
  • Financial Support
  • Reporting of Adverse Events, Product Complaints, Medical information Requests and other reportable safety information.
  • Specialty Pharmacy set up

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: 1-833-ALLY100 (1-833-255-9100)

Fax number: 1-833-255-9544

E-mail: ally@patientassistance.ca

Website: https://glatect.com/en/all-about-the-ally-program/

Hulio®

The Viatris Advocate™ patient support program offers patients prescribed Hulio a dedicated case manager, pre-requisites diagnostic testing support, injection training, reimbursement navigation and financial assistance as needed, flexible medication delivery services and treatment adherence reminder calls.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm (EST)

Toll free number: 1-844-485-4677

Fax number: 1-844-554-8546

E-mail: hulio@assistprogram.com

Website: www.Hulio.ca

Hyrimoz®

The XPOSE® by Sandoz Patient Support Program provides services that are designed to help patients get quickly started with HYRIMOZ® and support them throughout their treatment.

  • A dedicated support team that is available to assist patients and Health Care Providers with reimbursement, paperwork, prescription renewal reminders, record keeping of patient documents, and injection training services.
  • A seamless enrollment process flexible to Health Care Provider’s preference
  • Provincially expert reimbursement navigation and adapted financial assistance
  • Injection services with tailored options for patient convenience
  • Continually updated clinical support services, including TB testing, fecal calprotectin, TDM
  • Services and support adapted to each patient category and age group
  • Health management support and education for physicians, nurses and pharmacists
  • Specific services to assist community pharmacists supporting patients on biosimilars

To enroll a patient or have any of your questions answered, please contact the XPOSE® by Sandoz Patient Support Program either through our toll free number or e-mail address and speak with your Patient Care Specialist and/or Nurse Case Manager.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: (888) 449-7673

Fax number: (844) 449-7673

E-mail: xpose@sandozprogramsupport.ca

Idacio®

KabiCare is a responsive program, tailored to patients and health care providers. Offering high patient satisfaction through single point of contact Case Managers, reimbursement navigation, financial assistance, patient education nursing support as well as other services.

Hours of Operation: Monday to Friday 9:00 am to 5:00 pm

Toll free number: 1-888-304-2034

Fax number: 1-888-304-2014

E-mail: info@kabicare.ca

Website: www.kabicare.ca

Inflectra®

Registering to the PfizerFlex Patient Support Program gives:

  • Live support for questions about the program or treatment;
  • Reimbursement expertise;
  • Experienced team members to help you access your medication as quickly as possible;
  • Access to a reliable infusion/injection clinic network, staffed by qualified healthcare professionals;
  • Practical tools to help you navigate your treatment plan.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: 1-855-935-3539

Fax number: 1-833-958-3539

E-mail: inflectra@pfizerflex.com

Website: www.pfizerflex.ca

Riximyo®

The XPOSE® by Sandoz Patient Support Program provides services that are designed to help patients get started quickly with RIXIMYO® and support them throughout their treatment.

  • A dedicated support team that is available to assist patients and Health Care Providers with reimbursement, paperwork, prescription renewal reminders, record keeping of patient documents, and infusion services.
  • A seamless enrollment process flexible to Health Care Provider’s preference
  • Provincially expert reimbursement navigation and adapted financial assistance
  • A broad and open patient-centric network of infusion clinics
  • Continually updated clinical support services for patients
  • Health management support and education for physicians, nurses and pharmacists
  • Specific services to assist community pharmacists supporting patients on biosimilars

To enroll a patient or have any of your questions answered, please contact the XPOSE® by Sandoz Patient Support Program either through our toll free number or e-mail address and speak with your Patient Care Specialist and/or Nurse Case Manager.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: (888) 449-7673

Fax number: (844) 449-7673

E-mail: xpose@sandozprogramsupport.ca

Ruxience®

Registering to the PfizerFlex Patient Support Program gives:

  • Live support for questions about the program or treatment;
  • Reimbursement expertise;
  • Experienced team members to help you access your medication as quickly as possible;
  • Access to a reliable infusion/injection clinic network, staffed by qualified healthcare professionals;
  • Practical tools to help you navigate your treatment plan.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: 1-855-935-3539

Fax number: 1-833-958-3539

E-mail: ruxience@pfizerflex.com

Website: www.pfizerflex.ca

Semglee® and Kirsty®

The Viatris Advocate™ program is a financial support program for individuals prescribed a Viatris insulin biosimilar which includes a bridging program and a copay of up to 25%* of the cost of the prescription.

*Based on reasonable upcharge, mark-up, and customary pharmacy fee.

Unique certification number: 00001001VI

Group: 37437

For more information, contact Viatris Customer Service.

Hours of Operation: Monday to Friday 8:30 AM – 4:30 PM EST

Toll free number: 1-800-575-1379

E-mail: customerservice.ca@viatris.com

Website: www.semglee.ca / www.kirsty.ca

Simlandi®

JAMP Care provides a comprehensive package of services including:

  • Dedicated Local Nurse Field Case Managers, a single point of contact for enrollment support, injection training, and help throughout the patient’s journey
  • Laboratory and vaccination services, including: routine blood work, TB skin test, Quantiferon Gold (GRA) TB test, TDM, fecal calprotectin, QuantON cal testing, Shingrix, and more (like COVID-19)
  • Flexible and easy enrollment process
  • Fast reimbursement navigation support
  • Bridging (as needed)
  • Financial assistance (including Quebec)
  • Auxita: The online & EMR PSP platform Learn more! >
  • Patient Mobile First Web app for faster service and communications
  • Clinical testing and vaccinations
  • For patients:
    • Medication delivery
    • Educational materials
    • Injection training at-home or in-clinic
    • Welcome packages
    • Print & online value-added tools
  • Nurse Field Case Manager patient adherence and follow-ups with clinic
  • Pharmacy program trained support available as needed
  • Nutrition counselling available on demand

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: 1-855-310-5102

Fax number: 1-888-331-3432

E-mail: jampcare@supportprogram.com

Website: https://www.jampcare-support.ca/en/simland.html

Truxima®

A comprehensive program that provides personalized support to patients with rheumatoid arthritis, granulomatosis with polyangiitis (GPA, also known as Wegener's Granulomatosis) and microscopic polyangiitis (MPA) who have been prescribed Truxima®.

Through this simple and effective program, patients can speak directly with an expert case manager for advice and answers to a vast array of questions on related topics, such as product information, symptom management, instructions for the first infusion appointment, and treatment coverage.

Truxima® Teva Support Solutions® (Truxima® TSS) offers the following services to patients currently on Truxima®:

  • Unique point of contact
  • Reimbursement navigation
  • Financial assistance
  • Site-of-care coordination
  • Infusion appointment scheduling

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: 1-877-714-2469

Fax number: 1-833-981-2254

E-mail: tss.info@truximacanada.com

Website: https://www.tevacanada.com/en/canada/our-products/specialty-medicines/patient-support/

Yuflyma®

Celltrion Healthcare Canada offers CELLTRION CONNECT™, a patient-focused support program tailored to support patients and healthcare providers. The program provides guidance with reimbursement navigation, financial assistance, injection and nurse support services as well as pharmacy support services for patients throughout their treatment.

Hours of Operation: Monday to Friday, 8:00 am to 8:00 pm

Toll free number: 1-855-966-1648

Fax number: 1-855-966-2223

E-mail: support@celltrionconnect.ca

Website: https://celltrionconnect.ca/en/yuflyma/

Contact Information

For any questions about how this policy applies to you, please contact your specialist, doctor, nurse practitioner, or pharmacist.

For more information about the biosimilar policy, please contact the Ontario Public Drug Programs by email at DrugProgramsDelivery@ontario.ca or by calling 416-327-8109 or 1-866-811-9893 and pressing “1” for the Public Inquiries Officer.

1 Glatect® and Copaxone® are non-biologic complex drugs (NBCDs); however, this funding policy regarding biosimilars will apply to their funding.  As a result, on this webpage, references to an originator biologic include Copaxone® and references to a biosimilar include Glatect®.

2 Humalog® 200 units/mL KwikPen® 200U/mL Inj Sol-Pref Pen 5x3mL Pk (DIN 02439611) is excluded from this funding policy regarding biosimilars as no biosimilar is available for this strength.

For More Information

Call ServiceOntario, Infoline at:
1–866–532–3161 (Toll–free)
In Toronto, (416) 314–5518
TTY 1–800–387–5559.
In Toronto, TTY (416)327–4282
Hours of operation: Monday to Friday, 8:30 a.m. – 5:00 p.m.

 
 
 
 
  • Connect With Us
Facebook Twitter YouTube RSS